Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community

Kirollos Hanna • 21 Mar 2018
HOPA 2018
General

Here, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, gives an insight into his experience of the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. Dr Hanna also offers an insightful perspective into the benefits of HOPA and expresses his excitement for what is to come for the oncology pharmacy community.

More from Kirollos Hanna

Updates on immunotherapy options for metastatic urothelial carcinoma
3:45
Updates on immunotherapy options for metastatic urothelial carcinoma
Kirollos Hanna • 21 Mar 2018
HOPA 2018 updates on urothelial carcinoma: what is new?
1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna • 21 Mar 2018
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna • 21 Mar 2018
Looking towards the future: what is in store for the treatment of bladder cancer?
2:12
Looking towards the future: what is in store for the treatment of bladder cancer?
Kirollos Hanna • 21 Mar 2018

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals